Table 4-.
Univariable and Multivariable Analysis of Risk Factors for Second Primary Invasive Malignancy
| Variable | Univariable Model | Multivariable Model | ||
|---|---|---|---|---|
| Hazard Ratio | p-value | Hazard ratio | p-value | |
| Age (5-year increase) | 1.07 (0.95–1.20) | 0.27 | --- | --- |
| Sex (male vs female) | 1.04 (0.62–1.76) | 0.88 | --- | --- |
| Baseline Performance Status | 1.03 (0.65–1.65) | 0.89 | --- | --- |
| BMI (1 unit increase) | 0.98 (0.93–1.02) | 0.28 | --- | --- |
| Prior Lines Treatment | 0.94 (0.83–1.05) | 0.27 | --- | --- |
| Prior Treatment vs Untreated | 0.92 (0.48–1.77) | 0.80 | --- | --- |
| Prior Purine Nucleoside Analog | 0.95 (0.58–1.55) | 0.83 | --- | --- |
| Prior Alkylating Chemotherapy | 0.73 (0.45–1.20) | 0.22 | --- | --- |
| Prior Anti-CD20 mAb | 0.90 (0.50–1.63) | 0.72 | --- | --- |
| Smoking (ever vs never) | 2.61 (1.56–4.34) | 0.0002 | 2.76 (1.60–4.76) | 0.0003 |
| BTK Inhibitor (Acalabrutinib vs Ibrutinib) | 0.55 (0.25–1.19) | 0.13 | --- | --- |
| Platelets, 30 unit increase | 1.08 (0.99–1.17) | 0.09 | 1.10 (1.01–1.2) | 0.03 |
| IgG (2-fold increase) | 1.09 (0.80–1.48) | 0.59 | --- | --- |
| CD4 absolute (2-fold increase) | 0.90 (0.82–0.98) | 0.02 | --- | --- |
| CD8 absolute (2-fold increase) | 0.89 (0.83–0.95) | 0.0007 | 0.87 (0.81–0.93) | <0.0001 |
| NK absolute (2-fold increase) | 0.97 (0.90–1.04 | 0.38 | --- | --- |
| Deletion 11q22 | 1.88 (1.16–3.07) | 0.01 | --- | --- |
| Trisomy 12 | 1.09 (0.61–1.93) | 0.78 | --- | --- |
| Deletion 17p13 | 1.00 (0.61–1.66) | 1.00 | --- | --- |
| Deletion 13q14 | 1.13 (0.69–1.83) | 0.63 | --- | --- |
| IgVH (mutated vs unmutated) | 0.55 (0.25–1.21) | 0.14 | --- | --- |
CI- confidence interval, BMI- body mass index, mAb- monoclonal antibody, BTK- Bruton’s tyrosine kinase, NK- natural killer cell count, IgVH- Immunoglobulin variable heavy chain gene